It first came to prominence¼ as a 'tumour antigen' in the early 1980s, as an oncogene in the mid-1980s, and as a tumour suppressor in this decade.
Its heyday was¼ perhaps 1993, when it became Science's 'Molecule of the Year'. But it was certainly on the tips of many tongues again a year or two ago with the identification of its partner, MDM2, its interaction with cell-cycle control proteins, and the publication of the crystal structure.
Not to be confused with¼ p35, the baculovirus-encoded apoptosis inhibitor, p52, p54, or any other 'p number' protein.
Its known functions are¼ as a tumour suppressor -it arrests growth and can induce apoptosis; as both a transcriptional activator and a repressor; as a mediator of cell-cycle responses to DNA damage (see Figure) . So perhaps it's just as well it wasn't given a more descriptive name early in its career.
Other speculated functions include¼
does it really need more? Well, it seems to function in multicellular development and differentiation, too, and there's some evidence that it's an exonuclease. If you're beginning to think that researchers from all areas of biology are obsessed with p53, witness the number of grant applications claiming that studies of p53 will provide a cure for cancer, explaining the cell cycle, DNA repair and morphogenesis along the way.
Who are its known associates? MDM2 is a definite, being involved in p53 transcriptional responses and in the ubiquitin-mediated degradation of p53. There are numerous proteins for which in vitro interactions with p53 are claimed -including kinases and co-regulators -though in most cases the evidence is controversial.
Most likely to be mentioned by¼
someone at almost every conference you attend, but always in talks by David Lane, Arnold Levine, Geoffrey Wahl, Karen Vousden, Carol Prives and Moshe Oren, and usually by Bert Vogelstein.
So is there a mountain of publications on p53? At the last count, there were 11,226 papers that mention p53, according to Medline.
Does it have commercial potential?
A lot of people think so. The loss or malfunction of p53 is thought to contribute to the development of half of all cancers, so there's great interest in designing drugs to restore or enhance its activity. Don't say¼ "Didn't it used to be an oncogene?", or "If it's so crucial, how come p53 knockout mice live to a ripe old age? And how do flies and worms survive without it?" Do say¼ "p53 is crucial to understanding metazoan life." ???
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